PROTHENA CORP PUBLIC LTD CO PRTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-5.98
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.7M | -$244.1M | — | — | $280.5M |
| 2024 | $135.2M | -$122.3M | — | — | $486.9M |
| 2023 | $91.4M | -$147.0M | — | — | $561.4M |
| 2022 | $53.9M | -$116.9M | — | — | $622.0M |
| 2021 | $200.6M | $67.0M | — | — | $466.0M |
| 2020 | $853,000 | -$111.1M | — | — | $184.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.98 (distress)
- Working capital / assets 0.839
- Retained earnings / assets -4.12
- EBIT / assets -0.657
- Equity / liabilities 6.054
Source: SEC EDGAR filings · CIK 0001559053 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.